NuChem Sciences Inc.

NuChem Sciences Inc.

NuChem Sciences Inc., based in Saint-Laurent, Quebec, is the Canadian entity of Sygnature Discovery, a contract research organization founded in 2004 and headquartered in Nottingham, UK. The firm emerged from a rebranding alongside the UK parent, aligning under the Sygnature name to present a unified global brand. Sygnature employs more than 700 scientists from over 50 countries, with about 70% holding PhDs, and maintains six offices in the UK and Canada. Sygnature offers integrated drug discovery services spanning computer-aided drug design, protein science, bioscience, chemistry, drug metabolism, in vivo pharmacology, and formulation. The firm claims to have advanced more than 60 candidates since 2011, including 36 clinical assets, 2 approved drugs, and over 200 patents filed. Its customer base includes startups such as Sitryx and larger pharma firms like Corcept Therapeutics, with a stated retention rate above 90%. The firm reports a track record of more than 200 active projects and over 90% customer retention. No separate AUM or deployment figures are disclosed for NuChem Sciences or its parent. The entity operates as a wholly owned service provider, not as an investment vehicle with a capital base. The structural differentiator is Sygnature's stated lack of an internal drug pipeline, which positions it as a pure service organization with no competing internal programs. This model, combined with a presence in both Europe and North America, allows it to offer confidentiality and full commitment to client projects.